Suggested remit: To appraise the clinical and cost effectiveness of acalabrutinib and venetoclax with or without obinutuzumab within its marketing authorisation for previously untreated chronic lymphocytic leukaemia.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6232
Provisional Schedule
- Committee meeting: 1:
- 03 February 2026
- Expected publication:
- 22 April 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- AstraZeneca UK (acalabrutinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- African Caribbean Leukaemia Trust
- Anthony Nolan
- Black Health Agency for Equality
- Blood Cancer UK
- Cancer 52
- Cancer Black Care
- Chronic Lymphocytic Leukaemia Support Association
- Helen Rollason Cancer Charity
- Independent Cancer Patients Voice
- Kevin Kararwa Leukaemia Trust
- Leukaemia Cancer Society
- Leukaemia Care
- Leukaemia UK
- Lymphoma Action
- Macmillan Cancer Support
- Maggie’s Centres
- Marie Curie
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Tenovus Cancer Care
- WMUK
- Professional groups
- Association of Anaesthetists
- Association of Cancer Physicians
- Association of Surgeons of Great Britain and Ireland
- British Blood Transfusion Society
- British Geriatrics Society
- British Institute of Radiology
- British Oncology Pharmacy Association
- British Psychosocial Oncology Society
- British Society for Haematology
- British Society of Blood and Marrow Transplantation and Cellular Therapy
- British Society of Interventional Radiology
- British Transplantation Society
- Cancer Research UK
- NHS Blood and Transplant
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society and College of Radiographers
- UK Clinical Pharmacy Association
- UK CLL forum
- UK Oncology Nursing Society
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- AbbVie (venetoclax)
- Accord (bendamustine, fludarabine)
- Aspen (chlorambucil)
- Baxter Healthcare (cyclophosphamide)
- BeOne Medicines UK (zanubrutinib)
- Celltrion Healthcare UK (rituximab)
- Dr Reddy’s Laboratories (bendamustine)
- Gilead Sciences (idelalisib)
- Johnson & Johnson Innovative Medicine (ibrutinib)
- Pfizer (rituximab)
- Roche (obinutuzumab, rituximab)
- Sandoz (cyclophosphamide, rituximab)
- Sanofi (fludarabine)
- Seacross Pharmaceuticals (bendamustine)
- Zentiva (bendamustine)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Hospital Information Services –Jehovah’s Witnesses
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Cochrane Haematological Group
- Genomics England
- Institute of Cancer Research
- Leukaemia Busters
- Lymphoma Research Trust
- MRC Clinical Trials Unit
- National Institute for Health Research
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 July 2025 | Invitation to participate |
| 15 May 2025 | The Department for Health & Social Care has asked NICE to conduct an appraisal of Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-July 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 21 January 2025 - 18 February 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6232 |
| 21 January 2025 | In progress. Scoping commencing |
| 16 December 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual